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Purpose: To assess the effects of potassium adaptation on some biochemical parameters in diabetic 
rats treated with metformin. 
Methods: Diabetes was induced via intraperitoneal administration of streptozotocin in potassium-
adapted and non-adapted rats and, then metformin (350 mg/kg) was administered orally. The following 
parameters were then evaluated 24 h after drug administration: urine volume, plasma glucose, plasma 
and urine creatinine and creatinine clearance. Lipid profiles and plasma and urine urea were also 
determined. 
Results: The blood glucose of the potassium-adapted diabetic group was not significantly reduced on 
treatment with metformin, compared to non-adapted diabetic rats which were significantly reduced (p < 
0.05) on metformin treatment. The potassium-adapted group treated with metformin had significantly 
higher creatinine clearance (p < 0.05) than the non adapted group. Urine volumes for both the diabetic 
and the potassium-adapted diabetic rats were significantly lower (p < 0.05) on treatment with metformin. 
Conclusion: The results indicate that potassium adaptation induces resistance to treatment with 
metformin and increases creatinine clearance in diabetic rats.   
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INTRODUCTION 
 
Diabetes mellitus (DM) is a chronic metabolic 
disorder characterized by hyperglycemia as a 
result of the diminished production of insulin 
or mounting resistance to its action, hence 
tissues are unable to carry out the normal 
metabolism of carbohydrates, fats and 
protein. Chronic hyperglycemia during 
diabetes causes glycation of body protein 
thereby affecting eyes, kidney, nerves and 
arteries [1]. The classical symptoms of DM 
are polyuria (frequent urination), polydiapsia 
(increased thirst) and polyphagia (increased 
hunger) [2]. 
 
Metformin is used in non-insulin dependent 
diabetics without a tendency to ketosis in 
whom dietary carbohydrate restriction has not 
controlled hyperglycemia and who remain 
symptomatic. Its main use is in obese 
patients, because of its anorectic effect which 
aids weight reduction. The drug also exerts a 
useful additive effect in patients unresponsive 
to sulphonylureas alone. It is contra-indicated 
in patients at risk of lactic acidosis and in the 
following conditions; renal failure, alcoholics, 
cirrhosis, chronic lung disease, cardiac 
failure, mitochondrial myopathy, acute 
myocardial infarction and other serious 
intercurrent illness [3].  
 
The role of potassium adaptation in the 
reduction of blood pressure has previously 
been demonstrated [4]. However, data on the 
effect of potassium adaptation on  diabetes 
and in diabetic patients being treated with 
metformin are unknown. Hence, this study is 
geared towards providing information on the 
role of potassium adaptation in diabetic 




Drugs and chemicals 
 
Potassium chloride (Wells Brand, Nigeria), 
total cholesterol kit (Randox UK), triglyceride 
kit (Randox UK), high density lipoprotein kit 
(Randox UK), glucose oxidase kit (Randox 
UK), streptozotocin (Sigma-Aldrich, UK), 
metformin (Merck Sante) suspended in 3 % 
Tween 80. 
 
Stock solutions of drugs were stored in a 
refrigerator at 4ºC. All chemicals were of 




Wistar albino rats of both sexes weighing 
between 200 and 300 g were obtained from 
the Animal House, Department of 
Pharmacology and Toxicology, Faculty of 
Pharmacy, University of Benin. They were 
allowed free access to water or a particular 
solution and fed standard diet (Bendel Feeds 
and Flour Mills Ltd, Ewu, Edo State). 
Depending on the group, animals were 





Approval for the work was obtained from the 
Faculty of Pharmacy Ethical Committee on 
the use of animals for experiments, University 
of Benin, Benin City, Nigeria. The 
animals were handled according to standard 
protocols for the use of laboratory animals 
[5].  
 
Procedure for potassium adaptation 
 
The potassium-adapted rats were given 0.75 
% KCl solution orally for 5 weeks in place of 
tap water [6]. 
 
Induction of diabetes 
 
Experimental diabetes mellitus was induced 
in normal and potassium-adapted male and 
female adult Wistar rats by intra-peritoneal 
injection of 60 mg/kg streptozotocin [7] in a 
0.1 M citrate buffer solution.  
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Experimental protocols 
 
Four groups of fasted rats were used, with 
each group having 5 rats. Group A comprised 
normal healthy rats and served as control. 
Potassium-adapted normal rats were also 
placed in another group (B). Diabetic rats 
fasted over night (n= 5) were placed in group 
C. Group D comprised Potassium-adapted 
diabetic rats. All the groups were admini-
stered metformin (350 mg/kg) orally [8] and 
kept in separate metabolic cages for 24 h 
after drug administration. Thereafter 24 h 
urine and blood samples were collected from 
each rat. The blood samples were collected 
via cardiac puncture and introduced into 
lithium heparin bottles. These were spun and 
the plasma isolated. Plasma samples 
obtained were then analyzed for glucose, 
creatinine, triglycerides, total cholesterol, as 
well as HDL and LDL cholesterol, creatinine 
clearance and urea. Creatinine and urea in 
the urine samples were also analyzed.  
 
Statistics analysis  
 
Data are presented as the mean ± standard 
error of the mean (S.E.M). Comparison of 
data was made, where appropriate, by one-
way ANOVA (GraphPad Prism Software, UK, 
version 2.05a) with Tukey post hoc.   A value 
of p < 0.05 was applied to determine 
significant differences in all cases.  
RESULTS 
 
Effect on lipid profiles 
 
Table 1 shows the effect of potassium-
adaptation on the lipid profile of the diabetic 
rats treated with metformin to be significantly 
different from the metformin treated group. 
Treatment of the potassium-adapted diabetic 
group with metformin significantly increased 
total cholesterol (TC) and low density 
lipoprotein (LDL), while triglycerides (TG) 
were significantly decreased (p<0.05). The 
LDL of the diabetic group (D) was 
significantly (p<0.05) reduced on treatment 
with metformin. 
 
Effect of potassium-adaptation on 
creatinine and urea 
 
The effect of potassium adaptation on plasma 
and urine creatinine and urea (plasma and 
urine) of diabetic rats treated with metformin 
are presented in Table 2. The potassium-
adapted group treated with metformin (KM) 
had a significantly (p < 0.05) higher urinary 
creatinine than the non-adapted group, 
treated with metformin (Met). The plasma 
creatinine of the diabetic group treated with 
metformin (DMe) was significantly lower (p < 
0.05) than those of the diabetic rats (D). 
Treatment of the potassium diabetic group 
with metformin (KDM) significantly decreased 
 
Table 1: Effect of potassium adaptation on the plasma lipid profiles of streptozotocin-induced 
diabetic rats treated with metformin (350 mg/kg). 
 
Treatment         TC      HDL       LDL        TG 
C (2ml/kg) 61.81± 3.52 28.59± 3.42 22.86± 2.47 75.20± 10.93 
K 44.32± 5.95b 47.68± 1.75b 12.07± 2.80b 26.82± 6.94b 
Met 60.86± 1.57 42.94± 2.62b 12.56± 2.38b 26.79± 1.79b 
KM 66.00± 1.45 ad 21.65± 5.84 ad 37.08± 7.47ad 41.06± 1.48ad 
D 60.13± 6.35 20.12± 2.89 33.10± 3.42b 46.55± 7.87 
DMe  40.3 ± 4.01 27.41± 3.59 13.13± 2.88ab 58.0 ± 7.95 
KD  31.78± 2.54 ab 26.14± 2.50 -31.56± 4.46ab 186.0± 24.60ab 
KDM 42.32± 2.39 ac 32.33± 4.25 12.23± 2.30 ac 47.58± 8.36ac 
 
Values are mean ± SEM, n = 5; bp < 0.05 significantly different from control;  abp < 0.05 significantly different from 
the diabetic group,  acp < 0.05 significantly different from the potassium-adapted diabetic group and ad p < 0.05 
significantly different from the metformin-treated group.  
 
Owolabi & Omogbai 
Trop J Pharm Res, October 2012;11(5): 750 
Table 2: Effect of potassium adaptation on plasma and urinary levels of creatinine and urea of 
streptozotocin- induced diabetic rats treated with metformin (350 mg/kg). 
                                          
 Creatinine (mmol/l)                               Urea (mmol/l) 
Treatment   Plasma     Urine  Plasma        Urine 
C  (2ml/kg) 0.21±0.03 2.67±0.62 9.27±0.37 785.85±116.90 
K 0.09±0.01 b 1.77±0.13 9.44±0.42 469.39±62.26 b 
Met  0.13± 0.01 b 11.42± 2.39 b 7.23± 0.28 b 500.41±103.30 
KM  0.12± 0.01 30.25± 0.93 ad 25.37± 5.05 ad 199.50±58.31 ad 
D 0.26±0.03 2.64±0.46 11.23±0.49 b 473.33±81.50 b 
DMe 0.14± 0.01 ab 3.04±1.08 9.60± 0.50 ab 586.54± 113.90 
KD  0.45±0.03 ab 10.97±1.14 ab 12.47±2.35 319.20±51.15 
KDM 0.20± 0.01 ac 8.54± 0.22 7.06± 0.83 213.49± 37.65 
Values are mean ± SEM, n = 5; a p < 0.0001,  bp < 0.05 significantly different from control; abp < 0.05 significantly different 
from the diabetic group; acp < 0.05 significantly different from the potassium-adapted diabetic group; adp < 0.05 
significantly different from the glibenclamide-treated group.  
 
(p < 0.05) the plasma creatinine of the 
potassium diabetic group (KD). The 
potassium-adapted group treated with 
metformin had significantly different (p<0.05) 
plasma and urinary creatinine relative to the 
metformin-treated, non adapted group (Table 
2).  
 
Plasma urea in the diabetic group treated 
with metformin was significantly lower (p < 
0.05) than those of the diabetics. Treatment 
of the potassium-adapted diabetic group with 
metformin did not bring about any significant 
differences in plasma and urinary urea levels. 
 
Effects on fasting blood glucose and urine 
volume 
 
The effects of potassium adaptation on the 
blood glucose and urine volume are 
presented in Figures 1 and 2, respectively. 
Treatment of the diabetic rats with metformin 
(DMe) significantly (p < 0.05) lowered their 
blood glucose levels unlike in the diabetic 
rats adapted to potassium (KD), where 
metformin was unable to lower their blood 
glucose level. It was also observed that the 
potassium adapted diabetic rats had 
significantly higher (p < 0.05) blood glucose 
levels, compared with the non-adapted 
diabetic rats (D).  
 
Treatment of the diabetic and potassium 
adapted diabetic groups with metformin 
significantly reduced (p < 0.05) urine volume 
compared with both the untreated diabetic 





Fig 1: Effects of potassium adaptation on blood 
glucose of streptozotocin-induced diabetic rats 
treated with metformin (350 mg/kg). Values are 
mean ± SEM, n = 5; a p < 0.0001,  bp < 0.05 
significantly different from control; abp < 0.05 
significantly different from the diabetic group; acp < 
0.05 significantly different from the potassium-
adapted diabetic group; adp < 0.05 significantly 
different from the glibenclamide-treated group 
 
Effect on creatinine clearance 
 
The creatinine clearance of the metformin 
group was significantly higher than that of the 
control (Fig 3). The potassium-adapted group 
treated with metformin had a significantly (p < 
0.05) higher creatinine clearance than the 
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non-adapted group treated with metformin. 
Treatment of the diabetic group with 
metformin significantly (p < 0.05) reduced the 
creatinine clearance of the diabetics. 
. 
 
Fig 2: Effects of potassium adaptation on urine 
volume of streptozotocin-induced diabetic rats 
treated with metformin (350 mg/kg Values are 
mean ± SEM, n = 5; a p < 0.0001,  bp < 0.05 
significantly different from control; abp < 0.05 
significantly different from the diabetic group; acp < 
0.05 significantly different from the potassium-
adapted diabetic group; adp < 0.05 significantly 
different from the glibenclamide-treated group. 
 
Fig 3: Effect of potassium adaptation on creatinine 
clearance of streptozotocin -induced diabetic rats 
treated with metformin. Values are mean ± SEM, n 
= 5; a p < 0.0001,  bp < 0.05 significantly different 
from control; abp < 0.05 significantly different from 
the diabetic group; acp < 0.05 significantly different 
from the potassium-adapted diabetic group; adp < 
0.05 significantly different from the glibenclamide-
treated group.  
DISCUSSION 
 
Metformin is an oral hypoglycaemic agent 
that exhibits an antihpyerglycemic effect 
devoid of insulin release [8].  The blood 
glucose level of the untreated diabetic rats 
was significantly reduced on treatment with 
metformin, however that of potassium 
adapted diabetics significantly higher than 
that of the non-adapted diabetic rats were not 
lowered on treatment with metformin. This 
seems to suggest that potassium adaptation 
brings about resistance to the beneficial 
effects of metformin.   
 
The creatinine clearance of the potassium-
adapted diabetic group was not affected by 
treatment with metformin; however, increase 
in creatinine clearance was noted for both 
groups that received metformin (adapted and 
non-adapted), pointing to the ability of 
metformin to elevate creatinine clearance. 
This may point to a possible protective effect 
of metformin against renal abnormality [9]. 
The volume of urine for both the diabetic rats 
and the potassium-adapted diabetic rats were 
significantly lowered on treatment with 
metformin. Polyuria is a well known symptom 
of diabetes [3], effectively controlled on 
treatment with metformin. From results 
obtained it is clear that potassium adaptation 
increases urine output, however treatment 
with metformin in this group significantly 
lowered the urine output, to an almost 
acceptable level (using the control values as 
the acceptable) especially for the non-
adapted diabetics. 
 
The LDL cholesterol of the diabetic group, 
shown to be raised in this study, was 
significantly lowered on treatment with 
metformin. High levels of LDL cholesterol can 
signal medical problems like cardiovascular 
disease, hence it is sometimes referred to as 
bad cholesterol [10]. Treatment with 
metformin, as this study suggests, would be 
able to protect against cardiovascular risk by 
lowering of LDL and raising HDL. 
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Metformin treatment raised the HDL values in 
normal, diabetic and potassium adapted 
diabetic rats in comparison with the control.  
Increased levels of HDL usually protects 
against cardiovascular diseases, and low 
HDL cholesterol levels (< 40 mg/dL) increase 
the risk for heart disease [12].  As seen in 
other studies done, our study simply confirms 
that metformin treatment is thus 
advantageous to the diabetic because of both 
the increase and decrease in HDL and LDL 
respectively.  
 
The high triglyceride value observed in the 
potassium-adapted diabetic group (186 
mg/dl) was significantly reduced on treatment 
with metformin to 47.58 mg/dl. This again 
points to a protective effect as high 
triglycerides are often part of a group of 
conditions called metabolic syndrome. This 
syndrome increases the risk for heart disease 
as well as for diabetes and stroke [12].  
 
CONCLUSION   
 
This study shows that potassium adaptation 
induces resistance to treatment with 
metformin in diabetes mellitus, but seems to 
have an advantage in the treatment of 
diabetes mellitus in the absence of 
metformin, as indicated by increase in HDL 
as well as decrease in both LDL and 
triglycerides. Metformin may be a good option 
for diabetes mellitus in the absence of 
potassium adaptation because of its 
protective effect against cardiovascular risk.   
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